Spectrum Hopes For Synergies With Allos Acquisition Amid Phase III Setback
This article was originally published in The Pink Sheet Daily
Executive Summary
Spectrum issued a tender offer of $1.82 per share for Allos Therapeutics on the same day that it announced the Phase III failure of its bladder cancer drug.